Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, Plutzky J, Node K, Parkhomenko A, Rydén L, Wilding JPH, Mann JFE, Tuttle KR, Idorn T, Rathor N, Lincoff AM.
Colhoun HM, et al. Among authors: brown pm.
Nat Med. 2024 May 25. doi: 10.1038/s41591-024-03015-5. Online ahead of print.
Nat Med. 2024.
PMID: 38796653